Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Piazza

Showing results (391-400 of 402) with videos related to

Pageof 41
Sort By:
Biorxiv : the Preprint Server for Biology|February 23, 2026
ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
The Journal of Urology|January 10, 2004
First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statementIan M Thompson, Demetrius Albanes, Joseph W Basler, et al.
Oncogene|April 8, 2014
Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activityN Li, K Lee, Y Xi, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal AdenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Molecular Cancer|March 14, 2025
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 29, 2021
Suppression of Colon Tumorigenesis in Mutant <i>Apc</i> Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-CateninKevin J Lee, Wen-Chi L Chang, Xi Chen, et al.
Clinical Transplants|July 22, 2008
14th International HLA and Immunogenetics Workshop Prospective Chronic Rejection Project: a three-year follow-up analysisM Ozawa, P I Terasaki, R Castro, et al.
Pharmacological Reviews|March 13, 2025
Cyclic nucleotide phosphodiesterases as drug targetsMichy P Kelly, Viacheslav O Nikolaev, Leila Gobejishvili, et al.
Cancer Research|December 19, 2024
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal CancerJeremy B Foote, Tyler E Mattox, Adam B Keeton, et al.
Tissue Antigens|April 21, 2007
14th International HLA and Immunogenetics Workshop: report on the Prospective Chronic Rejection ProjectM Ozawa, P I Terasaki, J H Lee, et al.
Pageof 41

Showing results (391-400 of 402) with videos related to

Sort By:
Pageof 41
Biorxiv : the Preprint Server for Biology|February 23, 2026
ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
The Journal of Urology|January 10, 2004
First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statementIan M Thompson, Demetrius Albanes, Joseph W Basler, et al.
Oncogene|April 8, 2014
Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activityN Li, K Lee, Y Xi, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal AdenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Molecular Cancer|March 14, 2025
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinomaDhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 29, 2021
Suppression of Colon Tumorigenesis in Mutant <i>Apc</i> Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-CateninKevin J Lee, Wen-Chi L Chang, Xi Chen, et al.
Clinical Transplants|July 22, 2008
14th International HLA and Immunogenetics Workshop Prospective Chronic Rejection Project: a three-year follow-up analysisM Ozawa, P I Terasaki, R Castro, et al.
Pharmacological Reviews|March 13, 2025
Cyclic nucleotide phosphodiesterases as drug targetsMichy P Kelly, Viacheslav O Nikolaev, Leila Gobejishvili, et al.
Cancer Research|December 19, 2024
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal CancerJeremy B Foote, Tyler E Mattox, Adam B Keeton, et al.
Tissue Antigens|April 21, 2007
14th International HLA and Immunogenetics Workshop: report on the Prospective Chronic Rejection ProjectM Ozawa, P I Terasaki, J H Lee, et al.
Pageof 41